Brisbane BioTech Vaxxas has snared fresh US government funding to accelerate its needle free vaccination platform for COVID-19 applications, as the company courts private investors. Vaxxas on Tuesday announced it has been awarded a $3.2 million (US$2 million) funding prize from a US research authority to accelerate its work in collaboration with the University of Queensland….

The post Brisbane BioTech in the hunt for US vaccine prize appeared first on InnovationAus.com.

This post was originally published on InnovationAus.com.